‘Medically significant’ specified by the case reporter. For simplicity of presentation, the outcome ‘Not reported’ also includes those with missing or pending outcomes. aIncludes 11 patients with compatible COVID-19 symptoms but not evaluated further given negative PCR tests; bIncludes 18 patients who were asymptomatic; cFollow-up ongoing.
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with Cladribine Tablets
DJ and AN are employees of Merck KGaA, Darmstadt, Germany. AG is an employee of Merck, Aubonne, Switzerland, a division of Merck KGaA, Darmstadt, Germany.
• Letter to the editor reporting outcomes of patients receiving Cladribine Tablets who have contracted COVID-19 and have been reported to the Merck KGaA, Darmstadt, Germany Global Patient Safety Database (data cut-off 29 June 2020)
Analysis of Influenza and Varicella Zoster Virus Vaccine Antibody Titers in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets
Roy S, Boschert U
Presented at the ACTRIMS Virtual Congress, 25–27 February, 2021
• Retrospective analysis of seroprotective antibody levels against varicella zoster or seasonal influenza in patients who received vaccinations before or during treatment with Cladribine Tablets in the MAGNIFY-MS study
Evaluating the Impact of Cladribine Tablets on the Development of Antibody Titers: Interim Results from The CLOCK-MS Influenza Vaccine Substudy
• Contains information on seroprotective antibody levels against seasonal influenza in a subset of patients with relapsing-remitting MS and secondary progressive MS who received vaccinations during treatment with Cladribine Tablets in the CLOCK-MS study